Home » Annabelle Brough

Annabelle Brough

Senior Analyst

Annabelle Brough is a Senior Analyst at CBPartners

Connect with Annabelle Brough

annabelle.brough@cbpartners.com

LinkedIn

Published Articles

2019 NRDL: Insights for Future Pricing Negotiations in China

The 2019 NRDL update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas. CBPartners' blog post examines how these learnings can help shape future NRDL negotiations.

Strategic Thinking: The Global Drug Launch Pricing Dilemma

Several factors contribute towards manufacturers seeking new ways to develop global drug pricing strategies. Product launches vary based on geography; when comparing the USA to EU, access outcomes can vary significantly based on whether or not the pivotal trial design has been optimized for each region.

The Cancer Drugs Fund: Paving the Way for Earlier and More Sustainable Access to Promising New Drugs

In 2011, The Cancer Drugs Fund (CDF) was launched to help patients in England access cancer drugs that had been rejected by the NHS. CBPartners' European Center of Excellence discusses the benefits of early engagement with NICE for both manufacturers and patients alike.

NICE Invites Pharma to Start the Conversation Early, with a View Towards Shifting Away from ‘No’ as the Starting Point